Titer- and Intervention Timing-Dependent Functional Effects of AAV9-NeuroD1 Gene Therapy on Spinal Cord Injury.

Alex Roman, Maggie Sorensen, Ezequiel Marron Fernandez de Velasco, Ann M Parr, Andrew W Grande, Walter C Low

Abstract read

In one paragraph

Article in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alex RomanGraduate Program in Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0003-1500-9764

Maggie SorensenCollege of Biological Sciences, University of Minnesota, Minneapolis, MN 55455, USA.

Ezequiel Marron Fernandez de VelascoViral Vector and Cloning Core, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0003-0257-4457

Ann M ParrGraduate Program in Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA.

Andrew W GrandeGraduate Program in Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-6474-7969

Walter C LowGraduate Program in Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA.

Funding

State of Minnesota Office of Higher Education Spinal Cord injury and Traumatic Brain Injury Research Grant Programs 214551

6 · The paper itself

Abstract

Spinal cord injury (SCI) often results in varying degrees of motor and sensory dysfunction with limited potential for recovery. Research into in vivo astrocyte-to-neuron reprogramming has led to promising results that, if translated to SCI, could offer substantial therapeutic benefit by replenishing lost populations of neurons for functional restoration. Previous studies have shown that AAV9-mediated delivery of NeuroD1 is capable of reprogramming astrocytes into neurons in vivo after chronic SCI in rats. Here we evaluate the dose-dependent functional and neuroprotective potential of the NeuroD1 gene therapy platform for acute and subacute SCI in rats. The Cre-dependent, DIO-based AAV9-NeuroD1 gene therapy platform was administered directly into the spinal cord of female Long-Evans rats after moderate, thoracic level 8/9 contusion SCI at one of two intervention timepoints: immediately after injury (acute) or 1 week post-contusion (subacute). The viruses were administered at a titer of 10

Indexed as

AAV9astrocytein vivo reprogrammingNeuroD1neuroprotectionregenerative medicinespinal cord injury

Identifiers

PMID42651785

DOI10.3390/cimb48080786

PMCPMC13511481

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.